[DAB2IP expression in bladder transitional cell carcinoma and its correlation with clinical outcome]

Area of Science:

• Urology
• Oncology
• Molecular Biology

Background:

• Bladder transitional cell carcinoma (BTCC) is a significant health concern.
• Understanding molecular markers for BTCC progression is crucial for improved patient outcomes.

Purpose of the Study:

• To examine the expression of DAB2IP in BTCC tissues.
• To determine the correlation between DAB2IP expression and clinical characteristics and prognosis in BTCC patients.

Main Methods:

• Immunohistochemical staining was used to assess DAB2IP protein levels in 79 BTCC and 11 normal bladder tissues.
• Statistical analysis correlated DAB2IP expression with pathological grade, stage, lymph node metastasis, and survival rates.

Main Results:

• DAB2IP expression was significantly lower in BTCC tissues than in normal bladder epithelium.
• Reduced DAB2IP expression correlated with high-grade, invasive, and metastatic BTCC.
• Patients with high DAB2IP expression had a significantly better 3-year survival rate.

Conclusions:

• DAB2IP may function as a tumor suppressor in the development and progression of BTCC.
• DAB2IP warrants further investigation as a potential therapeutic target or prognostic biomarker for BTCC.